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Abstract: South  Asian  immigrants (SAIs) have  a higher prevalence of  cardiovascular  (CV) morbidity  and mortality  
compared with other populations. The major challenge associated with primary prevention of cardiovascular to coronary 
artery  diseases  (CAD)  in  SAIs  involves  early  and  accurate  detection  of  CAD  in  asymptomatic  individuals  at  high  
cardiovascular risk. Inflammatory processes are now recognized to play a central role in the pathogenesis of atherosclero-
sis and are found to be associated with future CV risk in a variety of clinical settings. Imaging measures, such as common 
carotid artery intima-media thickness (CCA-IMT), are being applied as surrogate markers for end-points, such as myocar-
dial  infarction  (MI)  and  death  in  clinical  trials.  Considering  high  CAD  risk  in  SAIs  and  knowing  that  conventional  
risk factors may not fully explain the excess CAD risk in this group, studies on the role of CCA-IMT in CAD prediction 
have been discussed. Also, C-reactive protein (CRP) validity in risk prediction, the role of dysfunctional high density 
lipoprotein (HDL) as a CAD risk marker in SAIs have been presented.  
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INTRODUCTION 
  Cardiovascular diseases (CVDs) account for more than 
15 million deaths each year in the world [1]. Many who die 
are under the age of 65 and given today's increased life span, 
these  deaths  are  premature.  South  Asians  are  individuals 
whose ethnic roots originate from the Indian subcontinent, a 
large  geographic  area  that  includes  India,  Pakistan,  Sri 
Lanka, Nepal, and  Bangladesh.  Collectively, South Asians 
represent one fifth of the global population [2-4]. In North 
America, more than 3.6 million South Asians live in the US, 
and although this group represents the second fastest grow-
ing  Asian  immigrant  population,  little  is  known  regarding 
their increased risk for CAD. It is important to recognize that 
the term “South Asian” refers to a heterogeneous population, 
with  important  differences  in  diet,  culture,  and  lifestyle 
among different South Asian populations and religions. Mul-
tiple studies of migrant South Asian populations have, how-
ever, confirmed a 3- to 5-fold increase in the risk for myo-
cardial infarction (MI) and cardiovascular death as compared 
with other populations [4-6]. Studies in the United Kingdom 
(UK) have found that South Asian Immigrants’ (SAIs) risk 
of CAD death is as much as 40% above whites’ [7,8]. In the 
US, South Asian Indian men have been found to have a rate 
of heart attacks that is nearly double  than  the general US 
population i.e. 7% vs. 3% [9]. Studies comparing CAD risk 
factors  amongst  Indians  living  in  India  to  immigrants  in 
Britain  [10]  highlight  that  CAD  risk  factors  are  markedly 
higher  amongst  Indian  Punjabi  [11]  and  Gujarati  [12]  
migrants  than  their  counterparts  in  India.  Traditional  CV  
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risk factors like hypertension, smoking or high cholesterol 
do not fully account for the increased CAD risk in SAs. Insu-
lin resistance is thought to be a contributory factor, but the 
exact  patho-physiological  mechanism  for  these  increased 
incidences in SAs awaits further insight. A study comparing 
SA  men  to  European  Caucasian  men  showed  elevated  
systemic arterial stiffening in SA men that could be partly 
responsible  for  the  high  CVD  burden  in  this  population.  
Increased insulin resistance may lead to arterial stiffening. 
Vessel wall composition in SAs may be another factor play-
ing a role [13]. Knowing the high prevalence of CAD and its 
risk factors  in South Asian immigrants, a major challenge 
associated with primary prevention of CAD involves early 
detection of CAD in those individuals who are at risk but are 
asymptomatic. Inflammatory mechanisms play a prominent 
role in mediating all stages of atherosclerosis, and measure-
ment  of  inflammatory  biomarkers  provides  a  method  for 
detecting  individuals  at  future  vascular  risk.  Advances  in 
cardiovascular  imaging,  especially  with  reference  to  com-
mon carotid artery intima media thickness (CCA-IMT), have 
the potential to improve the early detection of atherosclerotic 
vascular disease and quantify its progression. Clinicians and 
their patients are challenged with how best to integrate these 
emerging  modalities  into  clinical  practice  and  understand 
their implications as surrogate markers for clinical end points 
in trials. 
  We therefore, present here a review of literature and up-
dates on studies examining the role CCA-IMT in CAD pre-
diction. In addition, we have briefly touched upon implica-
tions of  C-reactive protein (CRP)  and its validity  in CAD 
risk prediction especially in SAIs. At the end of the review, 
we have provided insights on the dysfunctional HDL, and its 
potential role as CAD risk marker.  46    The Open Cardiovascular Medicine Journal, 2010, Volume 4  Sunita Dodani 
COMMON  CAROTID  ARTERY  INTIMA-MEDIA 
THICKNESS (CCA-IMT)  
  Assessment of CCA-IMT is well-recognized as a surro-
gate marker of atherosclerosis [14-20]. Moreover, CCA-IMT 
is a strong and independent predictor of death, stroke  and 
myocardial  infarction  (MI)  in  hypertensive  patients  with 
CAD referred for coronary angiography. CCA-IMT is one of 
the methods for the detection of early stages of atheroscle-
rotic disease and has been chosen as a surrogate marker over 
other non-invasive methods because it is a high-resolution, 
noninvasive  technique  that  is  readily  available,  allows  to 
visualize the vessel wall structure with high resolution [21].
 
Pignoli  and  others  established  that  the  distance  measured 
between two lines separated by a hypoechogenic space visi-
ble in an ultrasound image of the carotid distal wall corre-
lated with the thickness of the intima-media (IMT) layers of 
the artery measured in vitro and in vivo [22]. Later studies 
extended this measurement to the thickness of the focal ca-
rotid plaque, and this “composite thickness” was used as a 
marker  of  atherosclerotic  burden.  This  method  has  been 
widely  used  since  its  introduction,  and  validated  in  many 
cross-sectional  and  longitudinal  epidemiologic  and  clinical 
studies. In addition, carotid atherosclerosis (IMT >1.0 mm) 
was associated with severe coronary disease (odds ratio, 2.2; 
95% confidence interval, 1.2 to 4.0) in subjects undergoing 
elective coronary angiography [23].
 The American Society of 
Echocardiography’s  (ASE)  2008  consensus  statement  on 
CCA-IMT  defines  it  as  the  combined  thickness  of  the  
intimal  and  medial  layers  of  the  far  arterial  wall  of  the  
carotid  artery  [24].  Carotid  plaque  is  defined  as  focal  
arterial  wall  thickening  50%  greater  than  the  surrounding 
wall or a focal region of CCA-IMT >1.5 mm [25]. Although 
standard carotid duplex ultrasonography is primarily used to 
identify occlusive carotid plaque (advanced atherosclerosis), 
CCA-IMT  assessment  measures  arterial  wall  thickening  
(pre-atherosclerosis)  and  non-occlusive  plaque  formation 
(subclinical atherosclerosis).  
  According  to  data  published  after  the  completion  of  
major epidemiologic studies as the Atherosclerosis Risk in 
Communities (ARIC) Study [25, 26], the European British 
Heart Study [27] and the Rotterdam Study [28], the increase 
in IMT not only correlates with most of the known athero-
sclerotic risk factors such as systolic hypertension, total and 
Low Density Lipoprotein (LDL) cholesterol levels, cigarette 
smoking, high-sensitivity C-reactive protein (hsCRP) levels, 
diabetes, and others, but also increases the risk of cardiovas-
cular events. The results of the ARIC Study show that with 
an increase of 0.19 mm of the IMT, the risk of coronary dis-
ease increases by 69% in women and 36% in men [25, 26]. 
The risk of stroke  is 8.5 times higher for women  and 3.6 
times  higher  for  men  with  IMT  >  1  mm,  compared  with 
those with IMT <0.6 mm. 
  In  classic  screening  procedures,  there  is  a  strong  ten-
dency to concentrate on modifiable risk factors,  especially 
when the data collection is relatively simple and easily avail-
able (e.g., blood samples or blood-pressure measurements). 
However,  when  patients  are  treated  actively,  those  classic 
risk factors can lose their predictive value. Although levels 
of known CV risk factors vary in South Asians, they do not 
fully explain the differences in CAD rates [29]. The tradi-
tional approach to CAD risk assessment is based on identify-
ing and to a certain extent quantifying established CV risk 
factors. Several algorithms based on this approach are used 
[30,  31].  Among  these,  the  Framingham  Risk  Assessment 
Model  is the most widely  accepted. Although used exten-
sively and generally accepted, this model (as well as other 
algorithms based on similar approaches) has limitations. It is 
derived from a white  Caucasian population in the US and 
may be less applicable to other ethnic groups. Family his-
tory,  abdominal  adiposity,  inflammation,  CCA-IMT  and 
other factors shown to predict CV risk
 [31-33] are not incor-
porated in the Framingham risk score (FRS). Diabetes and 
smoking are  identified only as present or absent, although 
current evidence supports a continuous relationship between 
glycemia and tobacco exposure to CAD risk [34, 35]. Age is 
the overriding FRS determinant, ignoring the greater inter-
individual variation in atherosclerotic burden at older ages 
and often providing false reassurance at younger ages. Im-
portantly,  the  FRS  only  predicts  short-term  (10-year)  risk, 
although from a clinical perspective the life-long risk of de-
veloping CAD events is equally relevant [36]. Early detec-
tion of sub-clinical CAD in high risk South Asian at a young 
age could help prevent CV events and substantially reduce 
the level of death and disability attributable to CAD. Imag-
ing of arteries to identify and quantify the presence of sub-
clinical atherosclerosis has been suggested to further refine 
CV  risk  assessment.  Limited  published  data  is  available 
looking into the associations of CV factors with CCA- IMT 
in South Asians, especially in SAI groups. Anand et al. per-
formed a cross-sectional population study in 1015 Canadian 
adults  of  Caucasian  European,  South  Asian,  Chinese  and 
Aboriginal  ancestry  [35].  This  study  showed  that  22%  of 
SAIs who were categorized as low risk based on FRS had 
CCA IMT values of ≥75th percentile for age, sex and ethnic-
ity. Furthermore, CCA-IMT has been shown to be independ-
ently  associated  with  CAD  in  South  Asians  [36]  and  is  a 
reproducible clinical tool to evaluate atherosclerosis, predict 
coronary  artery  disease  and  show  the  effectiveness  of  
medical therapies [30, 37, 38]. We have shown in several  
of our studies on SAIs in the US that even without CAD or 
diabetes, positive CCA-IMT (≥ 0.8 mm) was seen in 40%  
of  homogeneous  multi-ethnic  SAI  groups  [39].  Moreover, 
positive  CCA-IMT  was  also  found  to  be  associated  with  
dysfunctional  HDL  (Dys-HDL)  after  adjusting  for  age,  
family  history  of  cardiovascular  disease,  and  hypertension 
(p=0.030) [40].  
  Increased CCA- IMT measurements have been employed 
to  predict  the  extent  and  severity  of  CAD  and  have  been 
found to be strongly associated with an increased risk of CV 
morbidity and mortality [41]. Similarly, reductions in CCA-
IMT  thickness  have  been  correlated  with  decreased  CAD 
morbidity and mortality and used as an end point surrogate 
marker of atherosclerosis regression and dyslipidemias im-
provement  in  patients  on  lipid  lowering  therapy  including 
SAIs [42]. There is need to identify sub-clinical CAD using 
atherosclerosis  surrogate  markers  like  CCA-IMT  in  SAIs 
that will help identify high-risk population for early preven-
tive strategies to reduce future risk of CAD.  
  Normal CCA-IMT values have been defined on the basis 
of  age  and  gender  distribution  curves  within  a  general 
healthy population, as reported in the ARIC study [43]. The 
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that are ≥75th percentile suggest risk higher than that pre-
dicted by the FRS and should be regarded as “high” values 
[24]. Values that fall within the 25th to 75th percentile range 
are  considered  “average”  and  should  not  affect  traditional 
risk estimates. Values that are ≤25th percentile are “low” and 
suggest risk lower than that predicted by the FRS. One of the 
biggest challenge faced by cardiologists and vascular physi-
cians is how best to interpret the results of trials using CCA-
IMT as the primary end point. Another challenge is how to 
integrate  new  imaging  measures  such  as  CCA-IMT  into 
clinical practice. The ASE concluded that measuring CCA-
IMT and identifying carotid plaque may be useful in evaluat-
ing  CV  risk  in  the  following  patient  populations  [24];  (1) 
patients with intermediate cardiovascular disease risk (6% to 
20% 10-year risk for myocardial infarction by the FRS), (2) 
patients  with  family  histories  of  premature  CVDs  in  first-
degree relatives; (3) patients aged <60 years with severe sin-
gle–risk  factor  abnormalities  (i.e.,  genetic  dyslipidemia), 
who would otherwise not be  candidates for pharmacother-
apy; and (4) women aged <60 years with ≥2 cardiovascular 
disease  risk  factors.  In  addition,  consensus  statement  also 
suggests that CCA-IMT can be used if the “burden of sub-
clinical vascular disease” is unclear or if evaluation for the 
degree  of  aggressiveness  of  therapy  is  needed  [24]  CCA-
IMT measurement has not been recommended for patients  
in  whom  the  results  would  not  change  treatment,  such  as 
patients with established CAD. 
  It is important to recognize that current recommendations 
for the clinical use of CCA-IMT are based on observational 
studies. The use of CCA-IMT ultrasound measurement visu-
alizes the long-term effects of different risk factors on the 
arterial  wall  and  on  the  development  of  atherosclerotic 
changes in a given patient. It allows the presence of athero-
sclerosis to be detected almost directly and, to some extent, 
semi-quantitatively. Due to slow changes, CCA-IMT dem-
onstrates the “overall atherosclerotic burden” and reflects the 
risk of death and of other CV events, even when classic risk 
factors  are  successfully  corrected  by  therapeutic  interven-
tions. Ultimately, prospective trials comparing the effective-
ness of CCA-IMT as a predictive tool of CV risk with that of 
other novel markers would best direct clinical recommenda-
tions for this imaging measure 
INFLAMMATORY BIOMARKERS 
  SAIs have higher CAD morbidity and mortality rates and 
conventional  risk  factors  do  not  explain  this  excess  risk. 
Thus, much attention has focused on whether plasma levels 
of  circulating  markers  of  vascular  inflammation  may  help 
identify SAIs at high risk for future CV events. Inflammation 
plays a central role in mediating all phases of atherosclerosis, 
from initial recruitment of circulating leucocytes to the arte-
rial  wall  to  the  eventual  rupture  of  the  unstable  plaque.  I 
hereby present recent updates on C-reactive protein (CRP) 
and dysfunctional HDL with special focus on SAIs in deter-
mining vascular events and the potential use of inflammatory 
bio-markers for cardiovascular risk prediction. 
C - Reactive Protein (CRP) 
  C-reactive protein (CRP) is a classical acute phase reac-
tant and a member of the pentraxin family of innate immune 
response proteins [44, 45]. CRP is mainly produced in the 
liver  in  response  to  interlukin  6  IL-6  and  thus  has  been 
thought of as an inactive downstream, by-stander marker of 
the inflammatory cascade. However, recent data suggest that 
CRP may play a direct role in atherogenesis. CRP is a proto-
typic marker of inflammation. Numerous prospective studies 
in  healthy  volunteers  have  confirmed  that  high-sensitivity 
CRP (hsCRP) predicts CV events, and hsCRP seems addi-
tive  to an elevated total  cholesterol level and a  total/high-
density  lipoprotein  (HDL)  cholesterol  ratio  in  men  and 
women  [46].  In  smokers  and  people  with  metabolic  syn-
drome, hsCRP levels are elevated; in elderly people, there 
seems to be a relationship between hsCRP and CV events 
and mortality [47]. Several properties of CRP make it proat-
herogenic;  however;  pending  further  studies,  it  should  be 
considered as a risk marker [48]. In people with acute coro-
nary syndromes, hsCRP measurement may be valuable [46]. 
Elevated  levels  in  the  highest  quantile  seem  to  predict 
greater mortality and poorer prognosis in patients with un-
stable angina and MI. While hsCRP is a strong independent 
predictor of risk of future MI, stroke, peripheral arterial dis-
ease,  and  vascular  death,  the  validity  of  hsCRP  as  a  risk 
marker needs to be assessed in all populations. Weight loss, 
statin drugs, aspirin, and high-dose alpha tocopherol therapy 
could affect hsCRP [48]. It has its greatest validity as an ad-
junctive measure in the primary prevention of cardiovascular 
disease. Data from two large statin trials suggest that testing 
for CRP may identify many patients without hyperlipidaemia 
who are at high risk for future cardiovascular events and who 
may benefit from statin therapy [49]. Once confirmed in on-
going large-scale prospective trials, screening for inflamma-
tion  using  CRP  as  a  biomarker  could  prove  an  important 
adjunctive  method  for  identifying  individuals  at  increased 
risk who would benefit most from targeted preventive inter-
ventions. Research on CRP is even more relevant in South 
Asians in general and SAIs in particular, since they are at 
high risk for the development of metabolic syndrome, type 2 
diabetes and CAD [50]. Sub-clinical inflammation is a recent 
addition to the long list of risk factors in SAIs. CRP levels in 
SAIs were reported to be higher than in Europeans [51, 52].
 
However,  the  precise  significance  of  high  CRP  levels  in 
SAIs is not known and definitive answers would be provided 
by the prospective studies correlating CRP levels in SAIs to 
the CV endpoints and glucose intolerance in long-term pro-
spective studies. Further, whether high CRP levels alone in 
young SAIs would influence future CV risk is not known. In 
summary, emerging evidence suggests that CRP is a robust 
marker for the prediction and prognosis of CAD and type 2 
diabetes however its impact remains to be ascertained. How-
ever, the significance of elevated CRP levels as a marker for 
CAD  in  populations  exposed  to  repeated  and  persistent  
infections in childhood is not clear. There is ongoing debate 
about the added value of measuring CRP concentrations to 
improve risk prediction, and that it may be premature. 
Dysfunctional HDL (Dys-HDL) 
  High density lipoprotein (HDL) is a heterogeneous lipo-
protein, containing several surface apolipoproteins (Apo AI, 
AII, AIV, C, E, J, and D). Apolipoprotein A-I (Apo A-I) is 
the principle protein of HDL, which also carries enzymes, 
such  as  paraoxonase  1  (PON  1),  platelet  activating  factor 
(PAF) –acetyl hydrolase, lecithin cholesterol acyl transferase 
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ferences in HDL particle size result mainly from the number 
of apolipoprotein molecules and the volume of the choles-
terol ester in the core of the particle [53].  
1.  HDL  has  antioxidant,  anti-inflammatory,  and  anti-
thrombotic properties that contribute to its function as an 
anti-atherogenic  agent.  Although  our  understanding  of 
how HDL protects against CAD is
 still incomplete, evi-
dence  supports  at  least  three
  major  athero-protective 
mechanisms of HDL.  
2.  HDL is an integral component of the reverse cholesterol 
transport process, functioning as a carrier
 of excess cellu-
lar cholesterol from peripheral tissues to the
 liver, where 
it is excreted from the body as bile acids and
 cholesterol. 
More  specifically,  HDL  mediates  efflux
  of  cholesterol 
from  cholesterol-loaded  macrophages  by  passive  diffu-
sion, through scavenger receptor B1 (SR B1), and, most 
significantly, via the protein Apo A-I [54, 55]. Apo A-I 
functions  through  an  ATP-binding  cassette  transporter 
A1  (ABCA1)  in  the  vessel  wall,  where  it  accepts  free 
cholesterol, forming pre-beta HDL that matures after es-
terification to cholesteryl esters (CE)  and then by leci-
thin-cholesterol acyltransferase to alpha migrating HDL 
[55].  
3.  A series of antioxidant enzymes which protect LDL from 
oxidation are associated with HDL. Oxidized lipids are
 
transferred  to  HDL  from  LDL  and  are  hydrolyzed  by 
HDL-associated  PON1,  LCAT,  and  platelet  activating 
factor (PAF) acetylhydrolase enzymes [56-58].file:///C:/ 
HDL  study/understanding  hDL.htm  -  R26-3425  The  
activities of  these  enzymes destroy oxidized  lipids  and 
also inhibit their formation. Removing the oxidized lipids 
initiates a positive feedback loop that results  in further 
activation  of  the  enzymes  and  further  destruction  of  
the  oxidized  lipids.  In  addition,  Apo  A-I  reduces  lipid 
peroxides within LDL, independent of PON1 [59]. 
  HDL may protect against CAD by selectively decreasing 
endothelial  cell  adhesion  molecules,  which  facilitate  the
 
binding of mononuclear cells to the vessel wall and promote
 
lesion development [60].  
  However, according to several recent studies, in patients 
with CAD, HDL is not only ineffective as an antioxidant but, 
paradoxically, appears to be pro-oxidant, as assessed by its 
lipid peroxide content [61-64]. In addition, HDL from pa-
tients with a history of CAD enhances the oxidation of LDL 
and  of  phospholipids  in  LDL  [62].  This  pro-inflammatory 
HDL, which is dysfunctional, accumulates oxidants that in-
hibit HDL-associated antioxidant enzymes, render Apo A-I 
unable to promote ABCA1 mediated cholesterol efflux, and 
promotes  the  formation  of  LDL-derived  oxidized  lipids. 
What makes HDL become dysfunctional is not clearly un-
derstood,  however  it  has  been  hypothesized  that  a  certain 
variant  of  Apo  A-I  susceptible  to  oxidation  and  nitration 
could be the culprit [65]. Current data indicates that a 1% 
increase  in HDL serum concentration can decrease
 cardio-
vascular  risk  by  2-3%,  independent  of  LDL  levels  [53]. 
However, HDL can have this protective effect only if it is 
functional. The incidence of dys-HDL in SAIs is not known, 
however several of the recent studies have shown prevalence 
of  Dys-HDL  in  SAIs  upto  50%  in  a  group  without  CAD 
[40]. Moreover, small available data have shown Dys-HDL 
association  with  CCA-IMT  [37].  Considering  Apo-A-I  
polymorphisms as a hypothesized cause of Dys-HDL, data in 
SAIs  found  six  novel  single  nucleotide  polymorphisms 
(SNPs) in Apo-A-I gene. One of those showed association 
with low HDL in SAIs [65], however association of Apo-A-I 
polymorphism with Dys-HDL is still work under progress 
and needs larger prospective studies.  
CONCLUSIONS 
  Given that SAIs are known to carry a disproportionately 
high risk for CAD and that traditional CAD risk factors may 
not fully explain the excess risk, there is a need to explore 
and understand other non-traditional risk factors. SAIs are 
under-represented  in  major  clinical  trials,  and  evidence-
based management strategies of CAD in this population are 
lacking. Most clinicians are aware of the low HDL levels in 
this group, but whether this is due to isolated low HDL lev-
els,  high  total  cholesterol/HDL  ratio,  or  an  elevated  non-
HDL level, is not known. Moreover, the quality of HDL and 
its role in CAD protection is rapidly emerging. The time has 
now come for CAD to be considered the number one public 
health problem in SAIs, the second largest Asian immigrant 
population  in  the  US.  Emerging  data  from  some  well-
planned  community-based  investigations  have  emphasized 
the  gravity  of  this  rapidly  increasing  epidemic.  The  good 
news is that the epidemiologic studies have already shown 
that the bulk of the  CAD  can be prevented or  at  least  its 
manifestations can be delayed. A multidisciplinary approach 
towards improving lifestyle methods involving the popula-
tion at risk, healthcare personnel, and the government is re-
quired  to  diminish  the  incidence.  From  SAIs’  perspective, 
there  is  a need for implementation of newer guidelines as 
well as lowering the threshold for initiating therapeutic in-
terventions. IMT may be helpful in predicting the occurrence 
of CV events in SAs that are asymptomatic but at a high risk 
due to additional factors after controlling for factors such as 
sex, age, any other clinical conditions and drug treatment the 
patient may be undergoing. IMT would be a good tool for 
therapeutic intervention, for monitoring the efficacy of stat-
ins, ACE inhibitors and other drugs in SAs. However, the 
assessment needs to take into account long term effects in 
IMT  for  the  same  patient,  to  control  for  any  pre-existing 
conditions that may cause inflammation [66]. With respect to 
the potential value of novel risk factors for CV risk predic-
tion, we illustrate why this work is very much in its infancy 
and currently not guaranteed to reach clinical utility. Indeed, 
the existence of several more powerful and easily measured 
predictors of diabetes, suggests that the additional value of 
novel markers may be limited. Ultimately, prospective trials 
comparing  the  effectiveness  of  CCA-IMT  as  a  predictive 
tool of CV risk with that of other novel markers would best 
direct  clinical  recommendations  for  this  imaging  measure. 
Nevertheless,  several  suggestions  to  improve  relevant  re-
search  are  given.  CCA-IMT  is  a  noninvasive  surrogate 
marker of atherosclerosis and proven to be helpful in detect-
ing  sub-clinical  CAD  by  stratifying  populations  at  highest 
risk for CAD. In addition, determining the presence of Dys-
HDL  in  SAIs  will  answer  several  questions  related  to  the 
presence of altered HDL level and function. This informa-
tion will not only help to stratify this high risk asymptomatic 
group, but will also be useful from a disease management 
point of view.  Atherothrombosis in South Asians  The Open Cardiovascular Medicine Journal, 2010, Volume 4    49 
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